List of Excipients in Branded Drug LEVONORGESTREL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
NuCare PharmaceuticalsInc	LEVONORGESTREL	levonorgestrel	68071-4126	LACTOSE MONOHYDRATE
NuCare PharmaceuticalsInc	LEVONORGESTREL	levonorgestrel	68071-4126	MAGNESIUM STEARATE
NuCare PharmaceuticalsInc	LEVONORGESTREL	levonorgestrel	68071-4126	SILICON DIOXIDE
NuCare PharmaceuticalsInc	LEVONORGESTREL	levonorgestrel	68071-4126	STARCH, CORN
NuCare PharmaceuticalsInc	LEVONORGESTREL	levonorgestrel	68071-4126	STARCH, POTATO
NuCare PharmaceuticalsInc	LEVONORGESTREL	levonorgestrel	68071-4126	TALC

Generic Drugs Containing LEVONORGESTREL

Company	Ingredient	NDC	Excipient
Rugby Laboratories	levonorgestrel	0536-1142	HYPROMELLOSE
Rugby Laboratories	levonorgestrel	0536-1142	LACTOSE MONOHYDRATE
Rugby Laboratories	levonorgestrel	0536-1142	MAGNESIUM STEARATE
Rugby Laboratories	levonorgestrel	0536-1142	SILICON DIOXIDE
Rugby Laboratories	levonorgestrel	0536-1142	STARCH, CORN
Rugby Laboratories	levonorgestrel	0536-1142	TALC

What are the Most Frequently-Used Excipients in LEVONORGESTREL?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
2	FD&C YELLOW NO. 6
1	HYDROGENATED COTTONSEED OIL
1	HYDROXYPROPYL CELLULOSE
5	HYPROMELLOSE

Excipient Strategy and Commercial Opportunities for Levonorgestrel

Last updated: February 26, 2026

How does excipient choice impact levonorgestrel formulations?

Levonorgestrel, a progestin used in emergency contraception, intrauterine devices, and oral contraceptives, requires specific excipient strategies to optimize stability, bioavailability, and patient compliance.

Typical excipients employed in levonorgestrel formulations include:

• Lactose monohydrate: Used as filler in oral tablets due to its compressibility and inertness.
• Hydroxypropyl methylcellulose (HPMC): Forms matrix in controlled-release tablets.
• Magnesium stearate: Serves as a lubricant.
• Polyvinylpyrrolidone (PVP): Acts as a binder.
• Polyethylene glycol (PEG): Utilized in cream or gel formulations.

Choice of excipients affects manufacturing processes, shelf life, and drug release profile, directly influencing product efficacy and market acceptance.

What are current trends in excipient strategies for levonorgestrel products?

Recent developments focus on enhancing patient safety and product stability:

• Use of novel non-lactose excipients: To accommodate lactose intolerance, formulations now incorporate alternatives like microcrystalline cellulose or hypromellose.
• Freeze-dried formulations: For emergency contraceptive pills, excipients like mannitol preserve drug stability during storage and transportation.
• Polymer-based controlled-release matrices: Enable sustained levonorgestrel release, reducing dosing frequency.
• Taste-masking agents: Improve oral compliance, especially in lower-dose formulations.

Advances tailor excipient choices to specific delivery modes and population needs, expanding commercial viability.

How do regulatory considerations influence excipient strategies?

Regulatory agencies, including the FDA and EMA, require detailed excipient profiles for approved levonorgestrel products:

• GRAS status: Excipients must be Generally Recognized As Safe.
• Allergen potential: Excipients like lactose may pose issues for some populations.
• Potential interactions: Excipients should not alter levonorgestrel’s stability or bioavailability.

Manufacturers must conduct extensive stability and compatibility testing, which influence formulation development and approval timelines.

What are commercial opportunities driven by excipient innovations?

Innovation in excipients opens new revenue streams:

• Niche formulations for special populations: Lactose-free or gluten-free levonorgestrel products. These address unmet needs and command premium pricing.
• Long-acting formulations: Controlled-release matrices using novel polymers. These products support once-daily or fewer doses, appealing for compliance.
• Combination products: Incorporating multiple contraceptives or adding non-contraceptive benefits, leveraging excipient platforms for multi-component formulations.

Market segmentation based on excipient-driven features can allow brands to differentiate and expand market share, especially in emerging markets.

What are the competitive implications for pharmaceutical companies?

Companies investing in excipient innovation gain:

• Product differentiation: Through improved stability, tolerability, and dosing convenience.
• Regulatory advantages: Faster approval pathways for novel formulations with well-characterized excipients.
• Market access: Cater to diverse populations with tailored products, expanding global reach.

However, development costs and regulatory scrutiny increase with innovation, requiring strategic planning and resource allocation.

Summary table: Excipient types and strategic implications for levonorgestrel products

Excipient Type	Purpose	Strategic Implication
Lactose monohydrate	Filler, inert carrier	Widely accepted, but allergen potential limits use
Hydroxypropyl methylcellulose	Controlled-release matrix	Enables sustained drug delivery
Magnesium stearate	Lubricant	Standard, cost-effective
Alternative fillers (e.g., microcrystalline cellulose)	Lactose-free formulations	Broaden patient eligibility
Novel polymers (e.g., polyethylene glycol derivatives)	Long-acting systems	Support premium product positioning

Key Takeaways

• Excipients influence formulation stability, bioavailability, patient compliance, and regulatory approval.
• Trends favor lactose-free options, controlled-release systems, and taste-masking methods.
• Innovation in excipients supports niche markets, monthly dosing, and combination therapies.
• Strategic formulation choices enable differentiation, regulatory advantage, and market expansion.
• High development costs necessitate careful resource planning and regulatory navigation.

FAQs

1. How do excipient choices affect levonorgestrel’s bioavailability?
Excipients influence drug release and absorption. For example, controlled-release polymers slow release, affecting onset and duration, while excipients like PVP improve dissolution.

2. Are there safety concerns regarding excipients in levonorgestrel products?
Yes. Excipients must be generally recognized as safe. Allergens like lactose may be unsuitable for some users. Regulatory agencies review excipient safety profiles.

3. What market segments benefit from novel excipient-based formulations?
Patients with lactose intolerance, those requiring long-acting contraceptives, and populations demanding high tolerability benefit most.

4. How does excipient innovation impact regulatory approval?
Innovative excipients require validation of safety, stability, and compatibility, potentially lengthening approval timelines but enabling differentiation.

5. What role do excipients play in expanding global access to levonorgestrel?
They facilitate formulations suitable for diverse climates, storage conditions, and patient needs, thus supporting broader distribution and acceptance.

---

References

[1] US Food and Drug Administration. (2022). Guidance for Industry: Excipients in FDA-Approved Human Drugs.
[2] EMA. (2021). Reflection Paper on Excipients in theوجه Design of Pharmaceuticals.
[3] Svensson, C., & Johansson, J. (2020). Advances in controlled-release formulations for oral contraceptives. International Journal of Pharmaceutics, 582, 119341.